EUVIMEDEUVIMED entdecken
Crossref

Neonatal Cholestasis: Exploring Genetic Causes and Clinical Outcomes

Neslihan Gürcan Kaya iD, Hakan Öztürk iD, Sinan Sarı iD, Ödül Eğritaş Gürkan iD, Buket Dalgıç iD

Journal of Paediatrics and Child Health · 2025

DOI: 10.1111/jpc.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Paediatrics and Child Health, 2025. Verfasst von Neslihan Gürcan Kaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Gastroenterology, Ankara Training and Research Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Cholestasis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neonatal cholestasis is a group of disorders characterised by conjugated hyperbilirubinemia in the newborns and young infants. Advances in genetic testing have facilitated the identification of specific aetiology. This study examines the genetic and clinical profiles of neonates with cholestasis, focusing on genotype–phenotype correlations and diagnostic outcomes.

Methods

A retrospective review of children with neonatal cholestasis treated between 1997 and 2024 was conducted. Extrahepatic causes were excluded, and genetic testing, including a targeted cholestasis panel and whole exome sequencing (WES), was employed. Clinical and biochemical data, including gamma‐glutamyl transferase (GGT) levels, were collected.

Results

Genetic disorders were identified in 28.0% of 378 cases, including mutations in ATP8B1, ABCB11, ABCB4, DCDC2, DGUOK, KIF12, USP53, and genes related to bile acid synthesis (HSD3B7, PEX1). GGT levels played a significant role in diagnosis: patients with low or normal GGT were frequently diagnosed with progressive familial intrahepatic cholestasis (PFIC)1 and 2, or bile acid synthesis defects, while high GGT levels were associated with PFIC3, alpha‐1 antitrypsin deficiency, and cystic fibrosis. Consanguinity was noted in 56.0% of genetically diagnosed cases. After 2010, 35.5% of patients received a genetic diagnosis, compared to 18.2% before 2010.

Conclusion

Genetic diseases are a major cause of neonatal cholestasis, and GGT levels serve as a useful diagnostic tool in differentiating subtypes. The increasing availability of genetic testing has improved early diagnosis and personalised management. Expanded genetic testing in clinical practice is critical for timely and accurate diagnosis of these rare disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisHumansInfant, NewbornRetrospective StudiesMaleFemalegamma-GlutamyltransferaseGenetic TestingMutationInfantGenetic Association Studies

Stichwörter der Autor:innen

gamma‐glutamyl transferasegenetic mutationsindirect bilirubinemianeonatal cholestasis

Substanzen

gamma-Glutamyltransferase

Autor:innen und Institutionen

  • Department of Pediatric Gastroenterology, Ankara Training and Research Hospital, Ankara, Turkey.
  • Department of Pediatric Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey.

ORCID-Profile: Neslihan Gürcan Kaya, Hakan Öztürk, Sinan Sarı, Ödül Eğritaş Gürkan, Buket Dalgıç

Zitieren

APA

Gürcan Kaya, N., Öztürk, H., Sarı, S., Eğritaş Gürkan, Ö., & Dalgıç, B. (2025). Neonatal Cholestasis: Exploring Genetic Causes and Clinical Outcomes. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.70072

Vancouver

Gürcan Kaya N, Öztürk H, Sarı S, Eğritaş Gürkan Ö, Dalgıç B. Neonatal Cholestasis: Exploring Genetic Causes and Clinical Outcomes. Journal of Paediatrics and Child Health. 2025. doi:10.1111/jpc.70072

BibTeX
@article{GrcanKaya2025,
  author = {Gürcan Kaya, Neslihan and Öztürk, Hakan and Sarı, Sinan and Eğritaş Gürkan, Ödül and Dalgıç, Buket},
  title = {Neonatal Cholestasis: Exploring Genetic Causes and Clinical Outcomes},
  journal = {Journal of Paediatrics and Child Health},
  year = {2025},
  doi = {10.1111/jpc.70072}
}
Kostenlos starten →